SCHEMBL2546101

SCHEMBL2546101

O=C(c1ccc(N2CCOC2=O)cc1)N1CCN(c2ccc(Cl)cc2Cl)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.52
ALDH1A1 P00352 7/20 0.47
LMNA P02545 5/20 0.47
TSHR P16473 2/20 0.47
HSP90AA1 P07900 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPSR1 Q6W5P4 3/20 0.47
USP2 O75604 2/20 0.47
KDM4E B2RXH2 2/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
MAPT P10636 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPK1 P28482 1/20 0.46
STAT3 P40763 1/20 0.46
HTT P42858 1/20 0.45
GAA P10253 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366377 0.81 HTT (0.62) ALDH1A1LMNATSHRSMN1; SMN2POLB
SCHEMBL2366430 0.78 MEN1 (0.44) ALDH1A1LMNATSHRSMN1; SMN2KDM4E
SCHEMBL2365973 0.78 HTT (0.57) ALDH1A1LMNATSHRSMN1; SMN2POLB
SCHEMBL2366055 0.77 KMT2A (0.50) ALDH1A1LMNATSHRSMN1; SMN2POLB
SCHEMBL2366309 0.77 KMT2A (0.50) ALDH1A1LMNATSHRSMN1; SMN2POLB
SCHEMBL2366564 0.77 ALDH1A1 (0.63) AKR1C3ALDH1A1LMNATSHRHSP90AA1
SCHEMBL2366091 0.77 HTT (0.56) AKR1C3ALDH1A1LMNATSHRHSP90AA1
SCHEMBL2366063 0.76 MGLL (0.68) MEN1KMT2A
SCHEMBL2546752 0.76 KMT2A (0.48) ALDH1A1LMNATSHRSMN1; SMN2POLB
SCHEMBL2365769 0.73 KMT2A (0.43) ALDH1A1LMNATSHRSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 AKR1C3 2186/4885ALDH1A1 598/4885LMNA 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.